The recent approvals of Leqembi (lecanemab) and Kisunla (donanemab) have refreshed the landscape of Alzheimer’s disease treatments. For the first time, patients have the option to take a drug ...
This option is one of the key differences between Kisunla and Leqembi, which was administered throughout its clinical trials. So at USC, doctors have a weekly meeting to discuss how patients are ...
There was no difference between the two dosing regimens ... the rate of ARIA-E and ARIA-H are a little higher with Kisunla than with Leqembi. The company said it plans to submit the TRAILBLAZER ...
The Mirror US on MSN8mon
FDA approves 'miracle' drug that can slow Alzheimer's by 'scraping brain plaque'compared to its rival Leqembi. However, experts caution against direct comparisons due to differences in patient groups ...
Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...
Both Kisunla and the other approved drug, Leqembi, have been shown to slow down the mental decline of Alzheimer's by more than 25%. But that's in a group of patients—an individual may do much ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback